Clinical Trials Logo

Low Vision clinical trials

View clinical trials related to Low Vision.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05904444 Completed - Clinical trials for Macular Degeneration

The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies

Start date: August 15, 2018
Phase: N/A
Study type: Interventional

Patients who develop macular diseases have several clinical complications,such as central vision loss, the central scotoma of the visual field, the decrease of reading speed and fixation stability. At present, there is still no satisfactory effect in the prevention and treatment of advanced macular disease. A new rehabitation strategy named microperimetric biofeedback training has been shown to be effective in improving patients' visual appearance, but there is no consensus regarding the optimal methodology and standard of practice. Therefore, we designed a prospective clinical study to verify the effectiveness of MBFT and to determine an optimal plan.

NCT ID: NCT05835193 Completed - Refractive Errors Clinical Trials

Pre-symptomatic Screening of Visual Acuity in Pre-school Students

Start date: April 20, 2023
Phase:
Study type: Observational

The present research process is a prospective, non-interventional clinical study that will be conducted -under the auspices of the Democritus University of Thrace (DUTH)- in the pre-school students of the city of Alexandroupolis, Greece. - The study aims to assess the visual acuity of the kindergarten students. - The measurement of monocular best-spectacle corrected visual acuity will be performed using a web-based visual acuity chart

NCT ID: NCT05491746 Completed - Clinical trials for Diabetic Retinopathy

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

DRTARES
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Diabetes has reached epidemic levels in North America and with it, diabetic retinopathy is increasingly affecting the vision of millions of people. Despite treatment many patients still have vision loss that cannot be improved medically or with prescription eyeglasses. Our study is going to look at an FDA Class 1 Exempted visual aid that uses augmented reality to help people see better.

NCT ID: NCT05243732 Completed - Depression Clinical Trials

Music Listening for Wellbeing in Adults With Acquired Visual Impairment

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

A visual impairment (VI) is often associated with reduced psychological wellbeing. Music can be used in a variety of ways to promote psychological wellbeing. Music intervention studies demonstrate that listening to music can provide a distraction from unpleasant thoughts/feelings. Hence, music may serve as a catalyst to improve mood and relieve feelings of depression, anxiety, and stress. The purpose of this study is to investigate if it is feasible for people with acquired VI to self-deliver daily music listening (music alone or with mindful music listening instructions) for wellbeing, in participants homes, for four-weeks, and to collect data remotely on efficacy in reducing symptoms of anxiety and depression and treatment fidelity.

NCT ID: NCT05209581 Completed - Refractive Errors Clinical Trials

Assessment of Visual Acuity in Refugee Population

Start date: January 24, 2022
Phase:
Study type: Observational [Patient Registry]

The present research process is a prospective clinical study that will be conducted under the auspices of the Democritus University of Thrace (DUTH) in the open accommodation structure for refugees and immigrants of Kavala, Kavala, Greece, and the Pre-Removal Detention Center (PROKEKA) for Foreigners of Kos, Kos, Greece. The study aims to assess the basic ophthalmological condition of the refugee/immigrant population and is developed in two main areas: 1. The recording of the ophthalmological care that the refugee/immigrant has received until his/her inclusion in the study through a structured questionnaire (eg previous examinations, spectacle utilization, pharmaceutical or other interventions, etc.) 2. The measurement of monocular best-spectacle corrected visual acuity in both eyes using a web-based visual acuity chart. Adult participants living in the two aforementioned centers will be recruited in a consecutive-if-eligible basis. All age groups will be proportionally represented (proportional age distribution).

NCT ID: NCT04974307 Completed - Low Vision Clinical Trials

Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision

Start date: September 30, 2021
Phase: N/A
Study type: Interventional

Background: CLN3 involves vision loss observed around the preschool years, with eventual progression to blindness within 1-3 years. Researchers want to test an assistive device that may help children with CLN3 or blindness. Objective: To learn if it is safe, easy, and useful for children with CLN3 or blindness to use the OrCam. Eligibility: People aged 6-18 years who have either CLN3-related disease or blindness. Design: Participants will be screened with the following: Medical history Physical exam Family history Eye exam and vision tests. They will get eyedrops to dilate their eyes. Psychological and neurocognitive tests. They will be asked questions and observed for how they do various tasks, such as talking, playing, writing, drawing, and solving problems. Hearing tests. They may wear headphones or earplugs. Electrodes may be taped to their head. Blood samples Skin biopsy, if needed Cheek cell, saliva, or urine samples The OrCam is the size of and weighs about half as much as a pack of gum. It is attached to eyeglass frames by magnets. Participants will do tasks before and after they have been trained on the OrCam. They will do these tasks without or with using the OrCam. Participants will be given an OrCam to use for 1 week or 1 month. They will have check-in sessions with the study team. Participants and/or their caregivers will be asked about abilities, behaviors, social skills, learning methods, intelligence, and health-related quality of life. Participants samples may be used for genetic testing and/or to make a type of stem cell. Participation will last for 1-5 weeks.

NCT ID: NCT04926974 Completed - Low Vision Clinical Trials

Community Access Through Remote Eyesight (CARE) Study

CARE
Start date: June 2, 2021
Phase: N/A
Study type: Interventional

Study is a randomized clinical trial evaluating the efficacy of novel mobile application technologies (including Seeing AI, Aira, and Supervision+) to improve quality of life in older adults with low vision by expanding community access and providing assistance with activities of daily living. Aira provides real-time remote personal assistance through a sighted Aira agent supplying direct feedback to assist with visual tasks. Seeing AI provides optical character recognition allowing any text to be read aloud, color identification, bar code reading, scene description, and facial recognition based on stored photos. Supervision + allows one to use the phone as a magnifier, providing magnification and contrast enhancement using the camera of the mobile phone. This study seeks to understand the potential of these technologies to improve daily activities, community participation, independence, and self-sufficiency in this group by examining a technological approach, which has not yet undergone rigorous investigation in a diverse population of older adults with visual impairment. Project objectives are to evaluate mobile applications in a wide range of visual disability, categorized into three groups: (1) mild to moderate visual acuity loss, (2) severe to profound visual acuity loss, and (3) legal blindness secondary to visual field loss. Participants are randomized to one of three intervention groups: (1) Supervision+ application, (2) Aira application, or (3) Seeing AI application for a period of 6 months. For the Aira intervention group, participants will be assigned either with 'restricted' access (current open access areas plus 30 minutes/month anywhere), or 'unrestricted' access (700 minutes), for a period of 3 months with a 3 month cross-over period. Participants may elect to continue the study for an additional 3 months during which time they have access to all 3 study mobile applications. Outcome measures include assessment of changes at three, six and nine months post-intervention for: visual ability, health state (including depression), self-efficacy, loneliness, life space, distances travelled from the home, and types of services obtained.

NCT ID: NCT04618224 Completed - Presbyopia Clinical Trials

Development and Validation of an Internet-based Near and Intermediate-vision Reading Test

wDDART
Start date: December 2, 2020
Phase:
Study type: Observational

Primary objective of our study is to develop and validate an internet-based digital near and intermediate-vision reading test in the greek language.

NCT ID: NCT04242836 Completed - Presbyopia Clinical Trials

Development and Validation of a Digital Optotype for Near Vision in Greek Language.

DeDART
Start date: March 28, 2019
Phase:
Study type: Observational [Patient Registry]

Primary objective of our study is to develop and validate a computer-based digital near-vision optotype based on the Greek version of the print MNREAD.

NCT ID: NCT03728660 Completed - Low Vision Clinical Trials

Design and Clinical Evaluation of a Smartphone-based Low Vision Enhancement System

eLVES
Start date: January 29, 2019
Phase: N/A
Study type: Interventional

The primary objective is to compare the effectiveness and adverse side-effects of the virtual bioptic telescope and virtual projection screen in a new head-mounted video-based low vision enhancement system (LVES) with a wide field of view to currently employed specifications for head-mounted video display low vision enhancement technology. Secondary objectives are to acquire qualitative information from patients to evaluate the functioning of the system, to optimize system features and operations, and to assess the value patients place on system features, functions, and operating parameters relative to those of current technology. Investigators will conduct a comparative effectiveness study to determine if the novel vision enhancing features of LVES 2 provide low vision patients with benefits superior to those provided by existing technology.